Afficher la notice abrégée

Associations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative

dc.rights.licenseopenen_US
dc.contributor.authorKOCHLIK, B.
dc.contributor.authorSTUETZ, W.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPERES, Karine
ORCID: 0000-0002-0720-0684
IDREF: 080634001
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFEART-COURET, Catherine
ORCID: 0000-0002-7959-1610
IDREF: 08195848X
dc.contributor.authorTEGNER, J.
dc.contributor.authorRODRIGUEZ-MANAS, L.
dc.contributor.authorGRUNE, T.
dc.contributor.authorWEBER, D.
dc.date.accessioned2020-06-25T09:20:11Z
dc.date.available2020-06-25T09:20:11Z
dc.date.issued2019-07-10
dc.identifier.issn2077-0383 (Print) 2077-0383en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8190
dc.description.abstractEnFrailty and sarcopenia are characterized by a loss of muscle mass and functionality and are diagnosed mainly by functional tests and imaging parameters. However, more muscle specific biomarkers are needed to improve frailty diagnosis. Plasma 3-methylhistidine (3-MH), as well as the 3-MH-to-creatinine (3-MH/Crea) and 3-MH-to-estimated glomerular filtration rate (3-MH/eGFR) ratios might support the diagnosis of frailty. Therefore, we investigated the cross-sectional associations between plasma 3-MH, 3-MH/Crea and 3-MH/eGFR with the frailty status of community-dwelling individuals (>65 years). 360 participants from two French cohorts of the FRAILOMIC initiative were classified into robust, pre-frail and frail according to Fried's frailty criteria. General linear models as well as bivariate and multiple linear and logistic regression models, which were adjusted for several confounders, were applied to determine associations between biomarkers and frailty status. The present study consisted of 37.8% robust, 43.1% pre-frail and 19.2% frail participants. Frail participants had significantly higher plasma 3-MH, 3-MH/Crea and 3-MH/eGFR ratios than robust individuals, and these biomarkers were positively associated with frailty status. Additionally, the likelihood to be frail was significantly higher for every increase in 3-MH (1.31-fold) and 3-MH/GFR (1.35-fold) quintile after adjusting for confounders. We conclude that 3-MH, 3-MH/Crea and 3-MH/eGFR in plasma might be potential biomarkers to identify frail individuals or those at higher risk to be frail, and we assume that there might be biomarker thresholds to identify these individuals. However, further, especially longitudinal studies are needed.
dc.language.isoENen_US
dc.subject.enLEHA
dc.subject.enSEPIA
dc.title.enAssociations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative
dc.title.alternativeJ Clin Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/jcm8071010en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31295923en_US
bordeaux.journalJournal of Clinical Medicineen_US
bordeaux.pageE1010en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209274
hal.version1
hal.date.transferred2021-04-27T08:23:45Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Medicine&rft.date=2019-07-10&rft.volume=8&rft.issue=7&rft.spage=E1010&rft.epage=E1010&rft.eissn=2077-0383%20(Print)%202077-0383&rft.issn=2077-0383%20(Print)%202077-0383&rft.au=KOCHLIK,%20B.&STUETZ,%20W.&PERES,%20Karine&FEART-COURET,%20Catherine&TEGNER,%20J.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_Jcm_Kocklik_2019.pdf
Taille:
279.1Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée